Abstract:Cis–trans isomerization of protein plays an important role in protein folding, function, and degradation, which is regulated by peptidyl‐proline isomerases (PPIases). The cis P‐tau but not trans P‐tau is resistant to protein dephosphorylation and degradation and also prone to protein aggregation and serves as an early driver of multiple neurodegenerative disease including Alzheimer disease (AD), traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and vascular contributions to cognitive impairment and dementia (VCID). Cis P‐tau antibody is the only clinical‐stage therapeutic for AD that has shown the efficacy in animal models of not only AD but also TBI and stroke, which are very early stages of dementia. In this article, we review the role of cis P‐tau in neurodegenerative diseases and its regulation as a potential drug target. A schematic drawing of cis and trans pT231P of tau protein. Cis but not trans P‐tau is induced by multiple stresses and contributes to neurodegenerative diseases. Cis P‐tau is converted into trans P‐tau by Pin1. Conventional tauopathies are a group of disease characterized by tau inclusions in the brains, including Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and certain types of frontotemporal dementia (FTD), among which AD is the most prevalent. Extensive post‐translational modifications, especially hyperphosphorylation, and abnormal aggregation of tau protein underlie tauopathy. Cis–trans isomerization of protein plays an important role in protein folding, function, and degradation, which is regulated by peptidyl‐proline isomerases (PPIases). Peptidyl‐prolyl cis–trans isomerase NIMA‐interacting 1 (Pin1), the only PPIase found to isomerize Pro following phosphorylated Ser or Thr residues, alters phosphorylated tau protein conformation at pT231‐P motif. The cis P‐tau but not trans P‐tau serves as an early driver of multiple neurodegenerative disease, encompassing AD, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and vascular contributions to cognitive impairment and dementia (VCID). Cis but not trans P‐tau is resistant to protein dephosphorylation and degradation, and also prone to protein aggregation. Cis P‐tau loses its ability to stabilize microtubule, causing and spreading tauopathy mainly in axons, a pathological process called cistauosis. The conformation‐specific monoclonal antibody that targets only the cis P‐tau serves as a very early diagnosis method and a potential treatment of not only conventional tauopathies but also nonconventional tauopathies such as VCID, with clinical trials ongoing. Notably, cis P‐tau antibody is the only clinical‐stage Alzheimer's therapeutic that has shown the efficacy in animal models of not only AD but also TBI and stroke, which are very early stages of dementia. Here we review the identification and pathological consequences of cis pt231‐tau, the role of its regulator Pin1, as well as the clinical implication of cis pt231‐tau conformation‐specific antibody in conventional and nonconventional tauopathies.

Tau Pathology Triggered by Spinal Cord Injury Can Play a Critical Role in the Neurotrauma Development

Cis P-Tau is Induced in Clinical and Preclinical Brain Injury and Contributes to Post-Injury Sequelae

O5‐04‐02: TRAUMATIC BRAIN INJURY INDUCES TAU AGGREGATION AND SPREADING

Antibody Against Early Driver of Neurodegeneration Cis P-tau Blocks Brain Injury and Tauopathy

Targeting cis-p-tau and neuro-related gene expression in traumatic brain injury: therapeutic insights from TC-DAPK6 treatment in mice

Post-traumatic neurodegeneration and chronic traumatic encephalopathy

Will Sirtuins Be Promising Therapeutic Targets for TBI and Associated Neurodegenerative Diseases?

Will Sirtuins Be Promising Therapeutic Targets for TBI and Associated Neurodegenerative Diseases

Neurobiochemical, Peptidomic, and Bioinformatic Approaches to Characterize Tauopathy Peptidome Biomarker Candidates in Experimental Mouse Model of Traumatic Brain Injury

Overexpression of pathogenic tau in astrocytes causes a reduction in AQP4 and GLT1, an immunosuppressed phenotype and unique transcriptional responses to repetitive mild TBI without appreciable changes in tauopathy

Function and regulation of cis P‐tau in the pathogenesis and treatment of conventional and nonconventional tauopathies

A Microtubule Stabilizer Ameliorates Protein Pathogenesis and Neurodegeneration in Mouse Models of Repetitive Traumatic Brain Injury.

Novel Mouse Tauopathy Model for Repetitive Mild Traumatic Brain Injury: Evaluation of Long-Term Effects on Cognition and Biomarker Levels After Therapeutic Inhibition of Tau Phosphorylation

Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC’s afferent and efferent connections

Proposed mechanisms of tau: relationships to traumatic brain injury, Alzheimer's disease, and epilepsy

Subcellular functions of tau mediates repair response and synaptic homeostasis in injury

Serum and Cerebrospinal Fluid Tau Protein Level As Biomarkers for Evaluating Acute Spinal Cord Injury Severity and Motor Function Outcome

Coding and long non-coding gene expression changes in the CNS traumatic injuries

Inflammasome links traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer's disease

Traumatic injury compromises nucleocytoplasmic transport and leads to TDP-43 pathology

cis P-tau Accumulation Triggers Neurodegeneration after Ischemic Stroke